TM Owner Eli Lilly
Mounjaro 2.5mg Vial
Global Shipping : Reliable Global Distribution Network
Express Delivery : Priority Shipping for Every Order
Secure Payments : Trusted Payment Protection System
Disclaimer
Secure Handling
24/7 Worldwide Support
Global Access
Worldwide Access to Health
Cold-Chain Expert
Excellence in Cold-Chain
Trusted Supply
Certified Medical Supply
Indications & Clinical Uses
- Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist, given by Eli Lilly as a prefilled pen or vial starting at 2.5 mg.
- In the US, Mounjaro is approved as an adjunct to diet and exercise to improve blood sugar control in adults and children aged 10 years and above with type 2 diabetes, and to reduce the risk of major cardiovascular events in adults with type 2 diabetes at high cardiovascular risk; it is not approved in the US for weight management under this brand.
- This differs from the EU label, where Mounjaro is also authorised for chronic weight management in adults with obesity or who are overweight with weight-related conditions, alongside a reduced-calorie diet and increased activity.
- In the US, tirzepatide for weight management is sold under the separate brand name Zepbound; the two products should not be confused.
- Mounjaro is given as a once-weekly self-injection under the skin of the abdomen, thigh or upper arm.
Side Effects
- Mounjaro carries a boxed warning: in rodent studies, tirzepatide caused thyroid C-cell tumours, and it is unknown whether this occurs in humans, so Mounjaro is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
- The most common reactions are gastrointestinal: nausea, diarrhoea, decreased appetite, vomiting, constipation, indigestion and abdominal pain, affecting up to about 1 in 5 patients and often easing as the dose is increased gradually.
- Serious but less common effects include acute pancreatitis, severe allergic reactions such as swelling of the face or difficulty breathing, gallbladder disease, and worsening of diabetic eye disease in patients already affected.
- Seek urgent medical help for severe abdominal pain that does not go away, signs of a severe allergic reaction, or a lump or swelling in the neck.
Precautions & Warnings
- Do not use Mounjaro if you or a family member has had medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, given the boxed warning on thyroid C-cell tumours.
- Stop Mounjaro and seek care immediately for persistent severe abdominal pain that may signal pancreatitis.
- Mounjaro is not recommended in people with severe gastroparesis, since it slows stomach emptying, and it should be used cautiously before surgery or procedures requiring general anaesthesia because of aspiration risk.
- Combining Mounjaro with insulin or a sulfonylurea increases the risk of low blood sugar, so monitoring and dose adjustment may be needed.
- It is given only by subcutaneous injection and must never be given intravenously or intramuscularly.
- Mounjaro is not recommended during pregnancy or breastfeeding, and each pen or vial is for single-patient use only and must never be shared.
Avoid Interactions
- Mounjaro can increase the risk of low blood sugar when combined with insulin or sulfonylureas, so the dose of these medicines may need to be lowered under medical supervision.
- Because tirzepatide slows gastric emptying, it can delay and reduce the absorption of oral medicines taken at the same time, which matters most for medicines with a narrow therapeutic range, such as warfarin; blood levels or effects of such medicines should be monitored, especially after starting Mounjaro or increasing the dose.
- Mounjaro may reduce the effectiveness of oral contraceptives, particularly during dose increases and for 4 weeks after each increase, so a non-oral or barrier contraceptive method is recommended during this time.
- Tell your healthcare provider about all other medicines, herbal products and supplements you take before starting Mounjaro.
References
Frequently Asked Questions
Mounjaro (tirzepatide) is used with diet and exercise to improve blood sugar control in adults and children aged 10+ with type 2 diabetes, and to lower cardiovascular risk in adults with type 2 diabetes at high risk. In the EU it is also approved for chronic weight management.
Mounjaro is a self-injection given under the skin of the abdomen, thigh or upper arm once weekly, any time of day, with or without food. Treatment usually starts at 2.5 mg weekly, increasing gradually every 4 weeks to a maintenance dose.
Mounjaro carries a boxed warning for thyroid C-cell tumours seen in animal studies. The most common side effects are nausea, diarrhoea, reduced appetite, vomiting and constipation. Seek urgent care for severe abdominal pain, signs of a severe allergic reaction, or a neck lump.
Never use Mounjaro if you or a family member has had medullary thyroid cancer or MEN 2 syndrome. Because it slows stomach emptying, it can affect other oral medicines and may reduce oral contraceptive effectiveness during dose increases -- use a non-oral method for 4 weeks after each increase.
If less than 4 days have passed since your missed dose, inject it as soon as you remember; if more than 4 days have passed, skip it and take your next dose on the regular weekly schedule. Never inject two doses close together to make up for a missed one.
Store unused Mounjaro pens or vials refrigerated at 2C to 8C, protected from light, and never freeze them. Once in use, a pen may be kept at room temperature (below 30C) for a limited period as directed on the label; always check the expiry date before use.
Trusted & Reliable – Your Partner in Global Distribution.
We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.
